Cargando…

Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly

CONTEXT: The somatostatin analogues octreotide LAR and lanreotide Autogel have been evaluated for the treatment of acromegaly in numerous clinical trials, with considerable heterogeneity in reported biochemical response rates. This review examines and attempts to account for these differences in res...

Descripción completa

Detalles Bibliográficos
Autores principales:	Colao, Annamaria, Auriemma, Renata S., Pivonello, Rosario, Kasuki, Leandro, Gadelha, Mônica R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2015
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4858561/ https://www.ncbi.nlm.nih.gov/pubmed/26519143 http://dx.doi.org/10.1007/s11102-015-0684-z

Ejemplares similares

The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly
por: Colao, Annamaria, et al.
Publicado: (2015)

The Future of Somatostatin Receptor Ligands in Acromegaly
por: Gadelha, Monica R, et al.
Publicado: (2021)

MicroRNA in Acromegaly: Involvement in the Pathogenesis and in the Response to First-Generation Somatostatin Receptor Ligands
por: Henriques, Daniel G., et al.
Publicado: (2022)

The genetic background of acromegaly
por: Gadelha, Mônica R., et al.
Publicado: (2017)

Novel therapies for acromegaly
por: Maia, Bernardo, et al.
Publicado: (2020)

SAT-433 Long-Acting Pasireotide Provides Clinical Benefit to Patients with Uncontrolled Acromegaly over Continued Treatment with First‑Generation Somatostatin Analogues (SSAs): Results from Phase 3b, Open-Label Study
por: Gadelha, Mônica, et al.
Publicado: (2019)

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs
por: Gadelha, Mônica, et al.
Publicado: (2020)

Acromegaly and Colorectal Neoplasm: An Update
por: Kasuki, Leandro, et al.
Publicado: (2022)

Determinants of morbidities and mortality in acromegaly
por: Kasuki, Leandro, et al.
Publicado: (2019)

Combined treatment of somatostatin analogues with pegvisomant in acromegaly
por: Franck, S. E., et al.
Publicado: (2015)

gsp Mutation Is Not a Molecular Biomarker of Long-Term Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Wildemberg, Luiz Eduardo, et al.
Publicado: (2021)

Glycemic profile in patients with acromegaly treated with somatostatin analogue
por: Valea, A, et al.
Publicado: (2015)

Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement
por: Chin, Sang Ouk, et al.
Publicado: (2019)

Association of Pathology Markers with Somatostatin Analogue Responsiveness in Acromegaly
por: Kontogeorgos, George, et al.
Publicado: (2022)

Association between dopamine and somatostatin receptor expression and pharmacological response to somatostatin analogues in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2017)

Clinical significance of filamin A in patients with acromegaly and its association with somatostatin and dopamine receptor profiles
por: Coelho, Maria Caroline Alves, et al.
Publicado: (2019)

miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly
por: Henriques, Daniel G., et al.
Publicado: (2023)

E‐cadherin expression is associated with somatostatin analogue response in acromegaly
por: Venegas‐Moreno, Eva, et al.
Publicado: (2019)

Approach to the Patient With Prolactinoma
por: Auriemma, Renata S, et al.
Publicado: (2023)

The Effect of Long Acting Somatostatin Analogue SMS 201-995 in Acromegaly
por: Choi, Chul Joon, et al.
Publicado: (1987)

Active postoperative acromegaly: sustained remission after discontinuation of somatostatin analogues
por: Alvarez-Escola, Cristina, et al.
Publicado: (2016)

Attitudes and preferences in patients with acromegaly on long-term treatment with somatostatin analogues
por: Follin, Cecilia, et al.
Publicado: (2016)

Metabolic effects of prolactin
por: Pirchio, Rosa, et al.
Publicado: (2022)

Glucose Abnormalities Associated to Prolactin Secreting Pituitary Adenomas
por: Auriemma, Renata S., et al.
Publicado: (2019)

Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
por: Strasburger, Christian J, et al.
Publicado: (2016)

Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms
por: Pivonello, Claudia, et al.
Publicado: (2022)

Pulmonary function testing and chest tomography in patients with acromegaly
por: Camilo, Gustavo Bittencourt, et al.
Publicado: (2013)

Clinical and functional variables can predict general fatigue in patients with acromegaly: an explanatory model approach
por: Michalski, André da Cunha, et al.
Publicado: (2019)

Control of acromegaly in more than 90% of patients after 10 years of pegvisomant therapy: an European referral centre real-life experience
por: Pirchio, R., et al.
Publicado: (2023)

Effects of combination therapy: somatostatin analogues and dopamine agonists on GH and IGF1 levels in acromegaly
por: VALEA, ANA, et al.
Publicado: (2015)

Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study
por: Shen, Ming, et al.
Publicado: (2018)

Combined therapy of somatostatin analogues with pegvisomant for the treatment of acromegaly: a meta-analysis of prospective studies
por: Ma, Lingyun, et al.
Publicado: (2020)

Long-term remission of acromegaly after somatostatin analogues withdrawal: a single-centre experience
por: Sala, E., et al.
Publicado: (2021)

On the Functional Capacity and Quality of Life of Patients with Acromegaly: Are They Candidates for Rehabilitation Programs?
por: Guedes da Silva, Débora Pedroza, et al.
Publicado: (2013)

Erratum to “Impact of Long-Acting Somatostatin Analogues on Glucose Metabolism in Acromegaly: A Hospital-Based Study”
por: Shen, Ming, et al.
Publicado: (2019)

Acromegaly Clinical Trial Methodology Impact on Reported Biochemical Efficacy Rates of Somatostatin Receptor Ligand Treatments: A Meta-Analysis
por: Carmichael, John D., et al.
Publicado: (2014)

Novel Somatostatin Receptor Ligands Therapies for Acromegaly
por: Paragliola, Rosa Maria, et al.
Publicado: (2018)

Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study
por: Pivonello, Rosario, et al.
Publicado: (2022)

SAT-LB076 T2-Signal Intensity, SST Receptor Expression and First-Generation Somatostatin Analogues Efficacy Predict Hormone and Tumor Responses to Pasireotide in Acromegaly
por: Coopmans, Eva, et al.
Publicado: (2019)

Effect of pasireotide on glucose- and growth hormone-related biomarkers in patients with inadequately controlled acromegaly
por: Schmid, Herbert A., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_i21fvl3cq19q3494sd1heq290f